SCM
ORMP icon

Sage Capital Management’s Oramed Pharmaceuticals ORMP Stock Holding History

Sage Capital Management’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$61.1K Buy
17,977
+1,227
+7% +$4.16K 0.03% 163
2025
Q4 		$47.7K Hold
16,750
– – 0.02% 161
2025
Q3 		$44.2K Hold
16,750
– – 0.02% 157
2025
Q2 		$37.7K Hold
16,750
– – 0.02% 157
2025
Q1 		$35.8K Hold
16,750
– – 0.02% 151
2024
Q4 		$40.5K Hold
16,750
– – 0.02% 154
2024
Q3 		$40.9K Hold
16,750
– – 0.02% 159
2024
Q2 		$43K Hold
16,750
– – 0.02% 152
2024
Q1 		$48.9K Buy
+16,750
New +$46.8K 0.03% 149

Other funds holding ORMP

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
AF
Aquamarine Financial George Town $1.37B AUM
Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $67.6B AUM 18.3% 1-Year Est. Return
GIA
Gem Investment Advisors Teaneck, New Jersey $102M AUM
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $25B AUM 18.87% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Sage Capital Management's ORMP Position: Q1 2026 in Review

Sage Capital Management increased its Oramed Pharmaceuticals (ORMP) stake by 7.3% in Q1 2026, buying an estimated $4.16K and bringing the position to 17,977 shares worth $61.1K. The position accounts for 0.03% of the portfolio, ranked #163.

Sage Capital Management first reported a position in ORMP in Q1 2024 and has held it in 9 quarters since. 64 funds tracked by Wall St. Rank hold ORMP as of Q1 2026.

  • Sage Capital Management held 17,977 shares of Oramed Pharmaceuticals worth $61.1K as of Q1 2026.
  • Sage Capital Management bought 1,227 Oramed Pharmaceuticals shares in Q1 2026, an estimated $4.16K.
  • Oramed Pharmaceuticals made up 0.03% of Sage Capital Management's portfolio in Q1 2026, its #163 holding.
  • Sage Capital Management first reported a position in Oramed Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
  • 64 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2026.

Based on Sage Capital Management's 13F filing for Q1 2026, filed 15 Apr 2026.